Please login to the form below

evolucumab

This page shows the latest evolucumab news and features for those working in and with pharma, biotech and healthcare.

Looks to boost sales after trial shows clear clinical advantage of PCSK9 inhibitor over statins

SMC rejects Amgen's Repatha over lack of outcomes data

The Scottish Medicines Consortium (SMC) has turned down Amgen's cholesterol-lowering treatment Repatha (evolucumab), citing a lack of “ robust” data.
NICE persuaded to back Praluent as well as Repatha

drug. The scheme includes an undisclosed discount to the NHS and allows NICE to back Praluent and Amgen's rival Repatha (evolucumab), which had already agreed a price cut, in new

More from news
Approximately 3 fully matching, plus 0 partially matching documents found.

Senior Medical Writer, Medical Communications, Relocate to Cardi...: Excellent Salary

Principal Medical Writer, Medical Communications, Relocate to Ca...: Excellent Salary

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

Account Director - Global Healthcare Advertising (Digital) - Lon...: £55000 - £65000

Senior / Principal Regulatory Writer – Home Working - UK or US: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

Editor > Senior Editor – Medical Education – London: Very competitive with excellent benefits

Digital Senior Account Director – Healthcare Advertising – Londo...: Salary TBC

FREELANCE Account Manager – Creative Healthcare Advertising – Lo...: SUPERB DAY RATES AVAILABLE

Head of Operations/ BUD, Healthcare PR, London – Excellent leade...: Excellent Package

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

Account Manager, Healthcare PR: £40, 000 – £42, 000 great benefits and bonuses

HOME BASED Senior Account Executive / Account Manager - Medical ...: Salary TBC

Add my company

WE ARE COUCH – a full service medical communications agency. We are a trusted partner; always striving to help make...

Why heading online for scientific meetings can yield greater HCP engagement: Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance: Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies: Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...